UBS Global Biopharma Conference 2026
Logotype for ALX Oncology Holdings Inc

ALX Oncology (ALXO) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for ALX Oncology Holdings Inc

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

ALX2004: EGFR antibody-drug conjugate

  • Phase I data expected in December 2026; the program was designed in-house, and clinical testing began ~12–13 months before the conference.

  • Matuzumab-derived binding epitope was selected based on prior clinical experience with fewer skin-related issues than cetuximab; the antibody internalizes at a similar rate to cetuximab.

  • Design priorities include reducing on-target rash, optimizing linker-payload potency and bystander effect, and keeping patients on treatment to enable payload delivery. No rash was seen in non-human primate studies.

  • Phase I study guidance increased to 35+ patients, including 15+ at relevant doses and in selected tumor types; enrollment shifted toward NSCLC and head and neck after reaching ~4 mg/kg.

  • Next development focus is second-line head and neck cancer and wild-type lung cancer, with assessment of EGFR-naive and EGFR-experienced patients; wild-type, especially squamous lung, was highlighted as an unmet-need setting.

Evorpacept: breast cancer phase II

  • ASPEN-09 is enrolling 120 patients with HER2-positive breast cancer to expand the data set before a potential phase III and refine the CD47 cut point.

  • The study uses HER2 status from archival or fresh tissue; sites are encouraged to obtain fresh biopsies, and ctDNA is also collected. Protocol CD47 status is defined as presence versus absence, with presence discussed as >5%.

  • Management estimated ~50% of enrolled patients may be confirmed HER2-positive and 50%–70% of those may be CD47-positive, depending on the cutoff.

  • The planned analysis compares outcomes by CD47 status; the primary endpoint discussed was response rate in HER2-confirmed, CD47-positive patients. Readout is expected in H2 2027.

  • Prior randomized gastric data showed increased response and durability with evorpacept added to a trastuzumab-based regimen; management cited real-world post-frontline HER2 treatment outcomes of 14%–15% ORR and 3–4 months’ PFS as a low benchmark.

Priorities and funding

  • Management said it aims to be nearing two registrational studies by this time next year, conditional on continued execution.

  • Management reported $159 million raised and stated cash runway through mid-2026, while describing funding as sufficient to reach key milestones.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ALX Oncology